SPS
ORIC icon

Susquehanna Portfolio Strategies’s Oric Pharmaceuticals ORIC Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,373
Closed -$144K – 1020
2026
Q1 		$144K Buy
+11,373
New +$129K ﹤0.01% 921
2025
Q4 		– Sell
-27,524
Closed -$330K – 1087
2025
Q3 		$330K Buy
+27,524
New +$290K 0.01% 914

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Susquehanna Portfolio Strategies's ORIC Position: Q2 2026 in Review

Susquehanna Portfolio Strategies sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 11,373 shares — an estimated $144K sold.

Susquehanna Portfolio Strategies first reported a position in ORIC in Q3 2025 and held it in 2 quarters. The position peaked at $330K in Q3 2025. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Susquehanna Portfolio Strategies reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 11,373 Oric Pharmaceuticals shares in Q2 2026, an estimated $144K.
  • Susquehanna Portfolio Strategies first reported a position in Oric Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Susquehanna Portfolio Strategies's Oric Pharmaceuticals position peaked at $330K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.